306 related articles for article (PubMed ID: 15201629)
21. Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats.
Funk CK; Zorrilla EP; Lee MJ; Rice KC; Koob GF
Biol Psychiatry; 2007 Jan; 61(1):78-86. PubMed ID: 16876134
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress.
Pelleymounter MA; Joppa M; Ling N; Foster AC
J Pharmacol Exp Ther; 2002 Jul; 302(1):145-52. PubMed ID: 12065711
[TBL] [Abstract][Full Text] [Related]
23. CRF1 and CRF2 receptors in the bed nucleus of the stria terminalis modulate the cardiovascular responses to acute restraint stress in rats.
Oliveira LA; Almeida J; Benini R; Crestani CC
Pharmacol Res; 2015; 95-96():53-62. PubMed ID: 25829333
[TBL] [Abstract][Full Text] [Related]
24. Effect of central corticotropin releasing factor on hepatic circulation in rats: the role of the CRF2 receptor in the brain.
Yoneda M; Nakamura K; Nakade Y; Tamano M; Kono T; Watanobe H; Shimada T; Hiraishi H; Terano A
Gut; 2005 Feb; 54(2):282-8. PubMed ID: 15647195
[TBL] [Abstract][Full Text] [Related]
25. Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors.
Overstreet DH; Knapp DJ; Breese GR
Pharmacol Biochem Behav; 2004 Feb; 77(2):405-13. PubMed ID: 14751471
[TBL] [Abstract][Full Text] [Related]
26. CRF
Kimbrough A; de Guglielmo G; Kononoff J; Kallupi M; Zorrilla EP; George O
Alcohol Clin Exp Res; 2017 Nov; 41(11):1886-1895. PubMed ID: 28833238
[TBL] [Abstract][Full Text] [Related]
27. Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor.
Gehlert DR; Shekhar A; Morin SM; Hipskind PA; Zink C; Gackenheimer SL; Shaw J; Fitz SD; Sajdyk TJ
Eur J Pharmacol; 2005 Feb; 509(2-3):145-53. PubMed ID: 15733549
[TBL] [Abstract][Full Text] [Related]
28. Central CRF2 receptor antagonism reduces anxiety states during amphetamine withdrawal.
Reinbold ED; Scholl JL; Oliver KM; Watt MJ; Forster GL
Neurosci Res; 2014 Dec; 89():37-43. PubMed ID: 25205625
[TBL] [Abstract][Full Text] [Related]
29. Urocortin, a novel neuropeptide with anxiogenic-like properties.
Moreau JL; Kilpatrick G; Jenck F
Neuroreport; 1997 May; 8(7):1697-701. PubMed ID: 9189917
[TBL] [Abstract][Full Text] [Related]
30. Chronic stimulation of corticotropin-releasing factor receptor 1 enhances the anxiogenic response of the cholecystokinin system.
Sherrin T; Todorovic C; Zeyda T; Tan CH; Wong PT; Zhu YZ; Spiess J
Mol Psychiatry; 2009 Mar; 14(3):291-307. PubMed ID: 18195718
[TBL] [Abstract][Full Text] [Related]
31. Modulation of Ca2+ influx by corticotropin-releasing factor (CRF) family of peptides via CRF receptors in rat pancreatic beta-cells.
Kageyama K; Kimura R; Suga S; Ogawa Y; Suda T; Wakui M
Peptides; 2006 Jul; 27(7):1814-9. PubMed ID: 16513211
[TBL] [Abstract][Full Text] [Related]
32. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide.
Spina M; Merlo-Pich E; Chan RK; Basso AM; Rivier J; Vale W; Koob GF
Science; 1996 Sep; 273(5281):1561-4. PubMed ID: 8703220
[TBL] [Abstract][Full Text] [Related]
33. Evidence supporting a role for corticotropin-releasing factor type 2 (CRF2) receptors in the regulation of subpopulations of serotonergic neurons.
Staub DR; Evans AK; Lowry CA
Brain Res; 2006 Jan; 1070(1):77-89. PubMed ID: 16403469
[TBL] [Abstract][Full Text] [Related]
34. Participation of corticotropin-releasing factor type 2 receptors in the acute, chronic and withdrawal actions of nicotine associated with feeding behavior in rats.
Kamdi SP; Nakhate KT; Dandekar MP; Kokare DM; Subhedar NK
Appetite; 2009 Dec; 53(3):354-62. PubMed ID: 19635511
[TBL] [Abstract][Full Text] [Related]
35. Effects of dorsal periaqueductal gray CRF1- and CRF2-receptor stimulation in animal models of panic.
Sergio Tde O; Spiacci A; Zangrossi H
Psychoneuroendocrinology; 2014 Nov; 49():321-30. PubMed ID: 25146701
[TBL] [Abstract][Full Text] [Related]
36. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III.
Pelleymounter MA; Joppa M; Ling N; Foster AC
Peptides; 2004 Apr; 25(4):659-66. PubMed ID: 15165722
[TBL] [Abstract][Full Text] [Related]
37. CRF receptor type 1 (but not type 2) located within the amygdala plays a role in the modulation of anxiety in mice exposed to the elevated plus maze.
Cipriano AC; Gomes KS; Nunes-de-Souza RL
Horm Behav; 2016 May; 81():59-67. PubMed ID: 27060334
[TBL] [Abstract][Full Text] [Related]
38. Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat.
Spina MG; Merlo-Pich E; Akwa Y; Balducci C; Basso AM; Zorrilla EP; Britton KT; Rivier J; Vale WW; Koob GF
Psychopharmacology (Berl); 2002 Mar; 160(2):113-21. PubMed ID: 11875628
[TBL] [Abstract][Full Text] [Related]
39. Brain region-specific regulation of urocortin 1 innervation and corticotropin-releasing factor receptor type 2 binding by ethanol exposure.
Weitemier AZ; Ryabinin AE
Alcohol Clin Exp Res; 2005 Sep; 29(9):1610-20. PubMed ID: 16205361
[TBL] [Abstract][Full Text] [Related]
40. Antagonism of cannabinoid 1 receptors reverses the anxiety-like behavior induced by central injections of corticotropin-releasing factor and cocaine withdrawal.
Kupferschmidt DA; Newman AE; Boonstra R; Erb S
Neuroscience; 2012 Mar; 204():125-33. PubMed ID: 21784132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
